Exploring COVID-19 Vaccine Side Effects: A Correlational Study Using Python

Canlas, Ferddie Quiroz; Nair, Sarachandran; Paat, Isabelo D

doi:10.1016/j.procs.2022.03.102

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, similar to our findings, a significant association between high BMI and post-vaccine side effects was not reported [47]. In general, there wasn't a significant correlation between the ABO blood type of participants and the occurrence of post-vaccination side effects in the current survey [51,55]. The evaluation of underlying disease in participants was performed.…”

Section: Plos Onesupporting

confidence: 76%

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study

Eterafi,

Fouladi,

Golizadeh

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

While the vaccination was introduced as a promising tool to control the Coronavirus disease 2019 (COVID-19) pandemic, concerns about vaccine-related side effects had grown. Due to the widespread administration of the COVID-19 vaccine worldwide for the first time, it was necessary to evaluate the safety and potential side effects in recipients. This study aims to assess, the incidence of adverse effects following Oxford-AstraZeneca vaccination and identify their related factors. In this cross-sectional survey-based study, 453 volunteers participated, including 235 men and 218 women. The reported adverse reactions from recipients of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine were collected by using a questionnaire. The findings showed that the incidence of adverse reactions, such as neurological, systematic, gastrointestinal, respiratory, and local symptoms were significantly higher after the first dose compared to the second dose. Systematic symptoms were the most prevalent reported side effects after the first and second dose injection. The demographical study of participants showed that individuals aged 18–34 and females were more prone to present adverse events following vaccination. However, no significant relationship was found between the occurrence of side effects and the recipients’ body mass index. Despite the life-saving role of vaccination against SARS-CoV-2, it may have some adverse reactions in recipients. The severity and frequency of side effects were different. So, they were dependent on several factors, including gender and age. Altogether, post-vaccination adverse reactions were mild and tolerable.

show abstract

Section: Plos Onesupporting

confidence: 76%

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study

Eterafi,

Fouladi,

Golizadeh

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…They also indicated that fever, fatigue, and headache were more common in Oxford/AstraZeneca compared with Sinopharm 42 . The diversity between the other studies and this study regarding the frequency of various side effects can be due to differences in delivered vaccines, sample sizes, study location, and other various factors that may influence the generalizability of the studies 43,44 . This study figured out that fever was more common in Oxford/AstraZeneca and Sputnik V, the adenoviral‐vector‐based vaccines, compared with COVAXIN and Sinopharm ( p value < 0.0001).…”

Section: Discussionmentioning

confidence: 58%

“…42 The diversity between the other studies and this study regarding the frequency of various side effects can be due to differences in delivered vaccines, sample sizes, study location, and other various factors that may influence the generalizability of the studies. 43,44 This study figured out that fever was more common in Oxford/ AstraZeneca and Sputnik V, the adenoviral-vector-based vaccines, compared with COVAXIN and Sinopharm (p value < 0.0001). Moreover, chills and myalgia were also more common in participants who received Sputnik V compared with other vaccines (p value = 0.006 for chills and p value = 0.025 for myalgia).…”

Section: Discussionmentioning

confidence: 86%

Evaluation of response to different COVID‐19 vaccines in vaccinated healthcare workers in a single center in Iran

Pourakbari

Mirbeyk

Mahmoudi

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Due to the recent coronavirus disease 2019 (COVID-19) pandemic and emergent administration of various vaccines worldwide, comprehensive studies on the different aspects of vaccines are in demand. This study evaluated antibody response after the second dose of the COVID-19 vaccine in the Children's Medical Center personnel. The blood samples of 174 healthcare workers were gathered at least 10 days after vaccination. The administered vaccines included Oxford/AstraZeneca, COVAXIN, Sinopharm, and Sputnik V. This study assessed all antibodies employing ELISA methods, including anti-SARS-CoV-2 neutralizing antibody by DiaZist and Pishtazteb kits, anti-SARS-CoV-2-nucleocapsid by Pishtazteb kit, and anti-SARS-CoV-2-Spike by Razi kit. The cutoff for the tests' results was calculated according to the instructions of each kit. Totally, 174 individuals with an average age of 40 ± 9years participated in this study, the proportion of men was 31%, and the frequency of past COVID-19 infection was 66 (38%). Sixteen (9%) personnel received Oxford/AstraZeneca, 28 (16%) COVAXIN, 29 (17%) Sinopharm, and 101 (58%) Sputnik V. anti-SARS-CoV-2-nucleocapsid and anti-SARS-CoV-2-Spike were positive in 37 (21%), and 163 (94%) participants and their mean level were more in adenoviral-vectored vaccines (p value < 0.0001). Neutralizing antibody was positive in 74% using Pishtazteb kit while 87% using DiaZist kit. All antibodies' levels were significantly higher in those with a past COVID-19 infection (p value < 0.0001). In conclusion, Oxford/AstraZeneca and Sputnik V had a similar outcome of inducing high levels of anti-SARS-Cov-2-spike and neutralizing antibodies, which were more than Sinopharm and COVAXIN. The titers of Anti-SARS-CoV-2-nucleocapsid antibody were low in all of these four vaccines.

show abstract

“…Diversos estudios corroboran los hallazgos de este trabajo, constatando que las reacciones más frecuentes tras la aplicación de las vacunas contra la COVID-19 fueron fiebre, cefalea, mialgias, escalofríos, astenia, reacción local, malestar general, náuseas (12,13,18,19,(25)(26)(27)(28)(29)(30) .…”

Section: Resultados Y Discusiónunclassified

“…Si bien ha comenzado a surgir paulatinamente diversas publicaciones con datos de efectividad de las vacunas COVID-19, sin embargo, a la fecha de inicio de la campaña de vacunación en el país, fueron escasas las informaciones disponibles del impacto de las vacunas contra COVID-19 (16)(17)(18) . Han sido reportados efectos adversos comunes asociados a la aplicación de las distintas vacunas, como dolor en el lugar de inyección; enrojecimiento e hinchazón, febrícula, dolor de cabeza, fatiga, dolores musculares, cansancio, escalofríos, cuadro pseudo gripal de corta duración, debilidad, vómitos, tos, disnea y diarrea (19)(20)(21) .…”

Section: Introductionunclassified

Efectos adversos asociados a las vacunas COVID-19 en funcionarios y estudiantes de la Facultad de Ciencias Químicas de la UNA, año 2021

Arrúa

Kennedy

Galeano

2023

Rev. Soc. cient. Parag.

View full text Add to dashboard Cite

La enfermedad COVID-19 es una enfermedad infecciosa causada por el virus SARS-COV-2, declarada emergencia de salud pública de importancia mundial y la vacunación fue planteada como la mejor herramienta contra esta enfermedad. Como ocurre con cualquier vacuna, algunas personas experimentan efectos secundarios leves o moderados después de vacunarse, por ello en este estudio se determinó la frecuencia de efectos adversos asociados a las vacunas contra la COVID-19 en funcionarios y estudiantes de la Facultad de Ciencias Químicas de la UNA durante el año 2021. Para el trabajo se realizó un estudio observacional analítico de corte transversal. La población accesible fueron los funcionarios y estudiantes de la FCQ-UNA, de ambos sexos, vacunados con las dos primeras dosis con cualquier vacuna contra la COVID-19, y que hayan accedido a participar del estudio dando su consentimiento informado. La obtención de datos se realizó aplicando una encuesta por Google Forms a la población accesible mediante muestreo no probabilístico de conveniencia por conglomerados. Las variables estudiadas fueron: sexo, edad, enfermedades de base, la clase de la vacuna recibida, las manifestaciones clínicas que presentaron después de la aplicación de las vacunas, y el tiempo de aparición de síntomas. De las 147 personas que cumplieron con los criterios de inclusión, el 85% eran del sexo femenino, el 68,7% tenían entre 20 a 29 años. El 60,5% de los participantes recibió la vacuna Pfizer, el 71,4% tenían antecedentes de COVID-19 y el 78,2% no tenía enfermedad de base. El 60,5% de la población de estudio presentó síntomas posteriores a la primera vacunación de COVID-19, y el 61,2% tras la segunda dosis. El tiempo de inicio de síntomas tras la administración de las vacunas fue mayormente entre 8 a 12 horas después de la vacunación tanto para la primera como para la segunda dosis. Se concluye que la mayoría de la población enfocada presentó efectos secundarios con la administración de ambas dosis, sin embargo, los síntomas fueron leves y en su mayoría aparecieron de 8 a 12 horas posterior a la aplicación.

show abstract

Exploring COVID-19 Vaccine Side Effects: A Correlational Study Using Python

Cited by 4 publications

References 13 publications

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study

Evaluation of response to different COVID‐19 vaccines in vaccinated healthcare workers in a single center in Iran

Efectos adversos asociados a las vacunas COVID-19 en funcionarios y estudiantes de la Facultad de Ciencias Químicas de la UNA, año 2021

Contact Info

Product

Resources

About